IDEXX Laboratories Analyst Ratings
IDEXX Laboratories Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/15/2023 | 8.21% | Stifel | $525 → $500 | Maintains | Hold |
| 08/03/2023 | 29.85% | Morgan Stanley | $590 → $600 | Maintains | Overweight |
| 08/02/2023 | 29.85% | JP Morgan | $550 → $600 | Maintains | Overweight |
| 08/02/2023 | 29.85% | Atlantic Equities | → $600 | Downgrades | Overweight → Neutral |
| 06/07/2023 | 29.85% | Atlantic Equities | → $600 | Reiterates | Overweight → Overweight |
| 05/03/2023 | 29.85% | Atlantic Equities | → $600 | Reiterates | → Overweight |
| 03/23/2023 | 27.68% | Morgan Stanley | $543 → $590 | Maintains | Overweight |
| 02/08/2023 | 27.68% | Barclays | $582 → $590 | Maintains | Overweight |
| 02/07/2023 | 19.03% | JP Morgan | $525 → $550 | Maintains | Overweight |
| 02/07/2023 | 29.85% | Atlantic Equities | $470 → $600 | Maintains | Overweight |
| 01/25/2023 | 14.7% | Goldman Sachs | $465 → $530 | Maintains | Buy |
| 11/15/2022 | 17.51% | Morgan Stanley | $573 → $543 | Maintains | Overweight |
| 11/02/2022 | 1.71% | Atlantic Equities | $490 → $470 | Maintains | Overweight |
| 10/17/2022 | -2.61% | JP Morgan | $525 → $450 | Maintains | Overweight |
| 08/05/2022 | 25.95% | Barclays | $700 → $582 | Maintains | Overweight |
| 08/04/2022 | 24% | Morgan Stanley | $603 → $573 | Maintains | Overweight |
| 08/03/2022 | 6.04% | Atlantic Equities | $500 → $490 | Maintains | Overweight |
| 07/26/2022 | -9.11% | Piper Sandler | $440 → $420 | Maintains | Overweight |
| 07/25/2022 | -10.19% | Stifel | $500 → $415 | Downgrades | Buy → Hold |
| 07/21/2022 | -5.86% | Goldman Sachs | $530 → $435 | Upgrades | Neutral → Buy |
| 07/12/2022 | -4.78% | Piper Sandler | → $440 | Initiates Coverage On | → Overweight |
| 06/24/2022 | 8.21% | Stifel | $575 → $500 | Maintains | Buy |
| 05/19/2022 | 14.7% | Goldman Sachs | $615 → $530 | Maintains | Neutral |
| 05/05/2022 | 30.5% | Morgan Stanley | $732 → $603 | Maintains | Overweight |
| 05/05/2022 | 1.71% | B of A Securities | $550 → $470 | Downgrades | Buy → Neutral |
| 02/08/2022 | 40.67% | Atlantic Equities | → $650 | Initiates Coverage On | → Overweight |
| 11/18/2021 | 58.41% | Morgan Stanley | → $732 | Initiates Coverage On | → Overweight |
| 08/13/2021 | 66.64% | Credit Suisse | $735 → $770 | Maintains | Outperform |
| 08/03/2021 | 32.01% | Goldman Sachs | $550 → $610 | Maintains | Neutral |
| 08/02/2021 | 62.31% | Barclays | $616 → $750 | Maintains | Overweight |
| 07/12/2021 | — | Guggenheim | Downgrades | Buy → Neutral | |
| 02/17/2021 | 29.85% | Barclays | → $600 | Initiates Coverage On | → Overweight |
| 01/29/2021 | 23.36% | JP Morgan | → $570 | Initiates Coverage On | → Overweight |
| 08/17/2020 | -8.67% | Credit Suisse | $415 → $422 | Maintains | Outperform |
| 07/30/2020 | -18.85% | Stifel | $280 → $375 | Maintains | Buy |
| 07/20/2020 | -15.6% | B of A Securities | $300 → $390 | Maintains | Buy |
| 05/01/2020 | -39.4% | Stifel | $266 → $280 | Maintains | Buy |
| 09/09/2019 | -40.05% | Goldman Sachs | → $277 | Initiates Coverage On | → Neutral |
| 08/16/2019 | -36.59% | Credit Suisse | $282 → $293 | Maintains | Outperform |
| 07/22/2019 | -36.16% | Stifel | $255 → $295 | Maintains | Buy |
| 05/23/2019 | -40.27% | Guggenheim | → $276 | Initiates Coverage On | → Buy |
| 05/02/2019 | -43.73% | Canaccord Genuity | $255 → $260 | Maintains | Buy |
| 11/05/2018 | -45.9% | Canaccord Genuity | $270 → $250 | Maintains | Buy |
| 11/02/2018 | -49.14% | B of A Securities | $275 → $235 | Maintains | Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 2023/09/15 | 8.21% | Stifel | $525→$500 | 维护 | 保持 |
| 08/03/2023 | 29.85% | 摩根士丹利 | $590→$600 | 维护 | 超重 |
| 08/02/2023 | 29.85% | 摩根大通 | $550→$600 | 维护 | 超重 |
| 08/02/2023 | 29.85% | 大西洋证券公司 | →$600 | 评级下调 | 超重→中性 |
| 06/07/2023 | 29.85% | 大西洋证券公司 | →$600 | 重申 | 超重→超重 |
| 05/03/2023 | 29.85% | 大西洋证券公司 | →$600 | 重申 | →超重 |
| 03/23/2023 | 27.68% | 摩根士丹利 | $543→$590 | 维护 | 超重 |
| 02/08/2023 | 27.68% | 巴克莱 | $582→$590 | 维护 | 超重 |
| 02/07/2023 | 19.03% | 摩根大通 | $525→$550 | 维护 | 超重 |
| 02/07/2023 | 29.85% | 大西洋证券公司 | $470→$600 | 维护 | 超重 |
| 2023年1月25日 | 14.7% | 高盛 | $465→$530 | 维护 | 买 |
| 2022年11月15日 | 17.51% | 摩根士丹利 | $573→$543 | 维护 | 超重 |
| 11/02/2022 | 1.71% | 大西洋证券公司 | $490→$470 | 维护 | 超重 |
| 10/17/2022 | -2.61% | 摩根大通 | $525→$450 | 维护 | 超重 |
| 08/05/2022 | 25.95% | 巴克莱 | $700→$582 | 维护 | 超重 |
| 08/04/2022 | 百分之二十四 | 摩根士丹利 | $603→$573 | 维护 | 超重 |
| 08/03/2022 | 6.04% | 大西洋证券公司 | $500→$490 | 维护 | 超重 |
| 07/26/2022 | -9.11% | 派珀·桑德勒 | $440→$420 | 维护 | 超重 |
| 07/25/2022 | -10.19% | Stifel | $500→$415 | 评级下调 | 购买→Hold |
| 07/21/2022 | -5.86% | 高盛 | $530→$435 | 升级 | 中性→购买 |
| 07/12/2022 | -4.78% | 派珀·桑德勒 | →$440 | 开始承保 | →超重 |
| 2022/06/24 | 8.21% | Stifel | $575→$500 | 维护 | 买 |
| 2022年05月19日 | 14.7% | 高盛 | $615→$530 | 维护 | 中性 |
| 05/05/2022 | 30.5% | 摩根士丹利 | $732→$603 | 维护 | 超重 |
| 05/05/2022 | 1.71% | B of A证券 | $550→$470 | 评级下调 | 购买→中性 |
| 02/08/2022 | 40.67% | 大西洋证券公司 | →$650 | 开始承保 | →超重 |
| 2021年11月18日 | 58.41% | 摩根士丹利 | →$732 | 开始承保 | →超重 |
| 2021/08/13 | 66.64% | 瑞士信贷 | $735→$770 | 维护 | 跑赢大盘 |
| 08/03/2021 | 32.01% | 高盛 | $550→$610 | 维护 | 中性 |
| 08/02/2021 | 62.31% | 巴克莱 | $616→$750 | 维护 | 超重 |
| 07/12/2021 | - | 古根海姆 | 评级下调 | 购买→中性 | |
| 02/17/2021 | 29.85% | 巴克莱 | →$600 | 开始承保 | →超重 |
| 2021/01/29 | 23.36% | 摩根大通 | →$570 | 开始承保 | →超重 |
| 2020/08/17 | -8.67% | 瑞士信贷 | $415→$422 | 维护 | 跑赢大盘 |
| 07/30/2020 | -18.85% | Stifel | $280→$375 | 维护 | 买 |
| 07/20/2020 | -15.6% | B of A证券 | $300→$390 | 维护 | 买 |
| 05/01/2020 | -39.4% | Stifel | $266→$280 | 维护 | 买 |
| 2019年09月09日 | -40.05% | 高盛 | →$277 | 开始承保 | →中性 |
| 2019年8月16日 | -36.59% | 瑞士信贷 | $282→$293 | 维护 | 跑赢大盘 |
| 2019年07月22日 | -36.16% | Stifel | $255→$295 | 维护 | 买 |
| 2019年05月23日 | -40.27% | 古根海姆 | →$276 | 开始承保 | →购买 |
| 2019年05月02日 | -43.73% | 卡纳科特·格纳奇 | $255→$260 | 维护 | 买 |
| 2018年11月05日 | -45.9% | 卡纳科特·格纳奇 | $270→$250 | 维护 | 买 |
| 11/02/2018 | -49.14% | B of A证券 | $275→$235 | 维护 | 买 |
What is the target price for IDEXX Laboratories (IDXX)?
IDEXX实验室(IDXX)的目标价格是多少？
The latest price target for IDEXX Laboratories (NASDAQ: IDXX) was reported by Stifel on September 15, 2023. The analyst firm set a price target for $500.00 expecting IDXX to rise to within 12 months (a possible 8.21% upside). 14 analyst firms have reported ratings in the last year.
Stifel于2023年9月15日报道了IDEXX实验室(纳斯达克代码：IDXX)的最新目标价。这家分析公司将目标价定为500.00美元，预计IDXX将在12个月内上涨至8.21%(可能上涨8.21%)。过去一年，有14家分析公司公布了评级。
What is the most recent analyst rating for IDEXX Laboratories (IDXX)?
IDEXX实验室(IDXX)的最新分析师评级是什么？
The latest analyst rating for IDEXX Laboratories (NASDAQ: IDXX) was provided by Stifel, and IDEXX Laboratories maintained their hold rating.
IDEXX实验室(纳斯达克代码：IDXX)的最新分析师评级由Stifel提供，IDEXX实验室维持持有评级。
When is the next analyst rating going to be posted or updated for IDEXX Laboratories (IDXX)?
IDEXX实验室(IDXX)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of IDEXX Laboratories, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for IDEXX Laboratories was filed on September 15, 2023 so you should expect the next rating to be made available sometime around September 15, 2024.
分析师在进行了广泛的研究后得出了股票评级，这些研究包括查阅公共财务报表，与IDEXX实验室的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。IDEXX实验室的上一次评级是在2023年9月15日提交的，因此您应该预计下一次评级将在2024年9月15日左右提供。
Is the Analyst Rating IDEXX Laboratories (IDXX) correct?
分析师评级IDEXX实验室(IDXX)正确吗？
While ratings are subjective and will change, the latest IDEXX Laboratories (IDXX) rating was a maintained with a price target of $525.00 to $500.00. The current price IDEXX Laboratories (IDXX) is trading at is $462.08, which is out of the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的IDEXX实验室评级维持不变，目标价在525.00美元至500.00美元之间。IDEXX实验室目前的交易价格为462.08美元，超出了分析师的预测范围。